Brain tumor drug repurposed: new combo therapy targets recurrent glioblastoma

NCT ID NCT05590689

Recruiting now Disease control Sponsor: Universität Münster Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a drug called 5-ALA, already used during brain tumor surgery, combined with radiotherapy for people whose glioblastoma has returned. The main goal is to find the safest dose and schedule of this combination. About 34 participants will be enrolled to see if the treatment is tolerable and may help control the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 5-Aminolevulinic acid (5-ALA, Gliolan)
What this could lead to: If successful, this could lead to a new treatment option for recurrent glioblastoma that combines a drug with standard radiotherapy to improve outcomes.
What could go wrong: This is an early-phase trial with only 34 participants, so results may not apply widely. The drug is being used in a new way, and side effects like neurological or blood toxicity are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

University Hospital Münster, Klinik für Neurochirurgie
RECRUITING

Münster, 48149, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.